LSA
CRDL

Lion Street Advisors’s Cardiol Therapeutics CRDL Stock Holding History

Lion Street Advisors’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-340,025
Closed -$461K – 262
2025
Q2 		$461K Buy
340,025
+6,300
+2% +$7.33K 0.14% 158
2025
Q1 		$318K Buy
333,725
+26,059
+8% +$32K 0.1% 197
2024
Q4 		$396K Buy
307,666
+34,385
+13% +$58K 0.13% 164
2024
Q3 		$544K Buy
273,281
+20,000
+8% +$41.5K 0.19% 120
2024
Q2 		$505K Buy
253,281
+60,581
+31% +$129K 0.19% 116
2024
Q1 		$161K Hold
192,700
– – 0.07% 247
2023
Q4 		$161K Buy
+192,700
New +$164K 0.07% 246

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Lion Street Advisors's CRDL Position: Q3 2025 in Review

Lion Street Advisors sold out of Cardiol Therapeutics (CRDL) in Q3 2025, closing a stake of 340,025 shares — an estimated $461K sold.

Lion Street Advisors first reported a position in CRDL in Q4 2023 and held it in 7 quarters. The position peaked at $544K in Q3 2024. 48 funds tracked by Wall St. Rank hold CRDL as of Q3 2025.

  • Lion Street Advisors reported no remaining Cardiol Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lion Street Advisors sold 340,025 Cardiol Therapeutics shares in Q3 2025, an estimated $461K.
  • Lion Street Advisors first reported a position in Cardiol Therapeutics in Q4 2023 and held it in 7 quarters.
  • Lion Street Advisors's Cardiol Therapeutics position peaked at $544K in Q3 2024.
  • 48 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2025.

Based on Lion Street Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.